BeyondSpring Inc.
BYSIDrugs in Pipeline
4
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
Docetaxel + Plinabulin (DP)
Non-Small Cell Lung Cancer
Plinabulin
Chemotherapy-induced Neutropenia
Pegfilgrastim
Chemotherapy-induced Neutropenia
Nitric Oxide
Bronchiolitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Docetaxel + Plinabulin (DP) | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Plinabulin | Phase 3 | Chemotherapy-induced Neutropenia | - | - |
Pegfilgrastim | Phase 3 | Chemotherapy-induced Neutropenia | - | - |
Nitric Oxide | Phase 3 | Bronchiolitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BeyondSpring Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in BeyondSpring Inc.'s (BYSI) pipeline across Phase 3. Its lead program is Docetaxel + Plinabulin (DP) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BeyondSpring Inc.'s next FDA catalyst?→
BeyondSpring Inc.'s (BYSI) next tracked catalyst is a Offering expected September 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BYSI biotech catalysts?→
Add BYSI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BeyondSpring Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.